Moderate mitral regurgitation in patients undergoing CABG--the MoMIC trial.

• BACKGROUND: The presence of mild to moderate ischemic mitral regurgitation (IMR) marks a significantly reduced long-term survival and increased hospitalizations due to heart-failure. However, it is common practice in many institutions to refrain from repairing the mitral valve in these patients. There are no available conclusive data to support this practice, and thus there is a need for an adequately powered randomized trial. STUDY DESIGN: The Moderate Mitral Regurgitation In Patients Undergoing CABG (MoMIC) trial is the first international multi-center, large-scale study to clarify whether moderate IMR in CABG patients should be corrected. A total of 550 CABG patients with moderate IMR are to be randomized to treatment of either CABG alone or CABG plus mitral valve correction. The primary end point is a composite end point of mortality and rehospitalization for heart failure at five years. The inclusion and randomization of patients started in February 2008. IMPLICATION: If correction of moderate IMR in CABG patients proves to be the superior strategy, most patients should be treated accordingly.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Blood Vessel Prosthesis Implantation

Coronary Artery Bypass

Coronary Artery Disease

complications

mortality

surgery

Heart Failure

etiology

mortality

Hospitalization

Humans

Mitral Valve Insufficiency

etiology

mortality

surgery

Myocardial Ischemia

etiology

mortality

surgery

North America

Research Design

Scandinavia

Severity of Illness Index

Time Factors

Treatment Outcome

regurgitation

ischemia

Mitral

trial

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)